✦ LIBER ✦

De Novo Peptide Design with C3a Receptor Agonist and Antagonist Activities: Theoretical Predictions and Experimental Validation

✍ Scribed by Bellows-Peterson, Meghan L.; Fung, Ho Ki; Floudas, Christodoulos A.; Kieslich, Chris A.; Zhang, Li; Morikis, Dimitrios; Wareham, Kathryn J.; Monk, Peter N.; Hawksworth, Owen A.; Woodruff, Trent M.

Book ID: 111686786
Publisher: American Chemical Society
Year: 2012
Tongue: English
Weight: 409 KB
Volume: 55
Category: Article
ISSN: 0022-2623
DOI: 10.1021/jm201609k

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

De novo protein design of agonists and a

De novo protein design of agonists and antagonists of C5a receptors

✍ Peter N. Monk; Meghan L. Bellows-Peterson; James Smadbeck; Christodoulos A. Flou 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Designing of an orally active complement

Designing of an orally active complement C3a agonist peptide with anti-analgesic and anti-amnesic activity

✍ Yunden Jinsmaa; Yasuuki Takenaka; Masaaki Yoshikawa 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 536 KB

Theoretical studies, synthesis, and biol

Theoretical studies, synthesis, and biological activity of 1-[(4-methylphenyl)sulfonyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carbonitrile (C9) as a non-peptide antagonist of the arginine vasopressin V1a and V2 receptors

✍ Contreras-Romo, M. Citlalli; Correa-Basurto, José; Padilla-Martínez, Itzia; Mart 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 611 KB